A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis

As the modulation of serine/arginine-rich splicing factor 3 (SRSF3) may be therapeutically beneficial to colorectal cancer (CRC) treatment, the identification of novel SRSF3 inhibitors is highly anticipated. However, pharmaceutical agents targeting SRSF3 have not yet been discovered. Here, we propos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yawen, Wang, Mengmeng, Meng, Fanyi, Yang, Man, Chen, Yinshuang, Guo, Xuqin, Wang, Weiwei, Zhu, Yifan, Guo, Yundi, Feng, Chunlai, Tian, Shen, Zhang, Hongjian, Li, Huanqiu, Sun, Jing, Wang, Weipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061822/
https://www.ncbi.nlm.nih.gov/pubmed/35501301
http://dx.doi.org/10.1038/s41420-022-01039-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061822/
https://www.ncbi.nlm.nih.gov/pubmed/35501301
http://dx.doi.org/10.1038/s41420-022-01039-9

Ejemplares similares